Emmes Announces Its Work on a Phase III Clinical Trial for Breakthrough Therapy Designation Product

Emmes announced that it provided the Phase III clinical trial support for a new investigational cell therapy that offers a promising treatment opportunity for patients who need an allogeneic bone marrow transplant.
[Emmes (PR Newswire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

Allogeneic Cord Blood Transfusions Prevent Fetal Haemoglobin Depletion in Preterm Neonates. Results of the CB-TrIP Study

Investigators monitored fetal haemoglobin levels in 25 preterm neonates until 36 weeks of post‐menstrual age; patients received repeated red blood cell (RBC) units from allogeneic cord blood (cord‐RBCs) or from adult donors, depending on whether cord‐RBCs were available.
[British Journal of Haematology]
Teofili, L., Papacci, P., Orlando, N., Bianchi, M., Molisso, A., Purcaro, V., … Stefano, V. D. (n.d.). Allogeneic cord blood transfusions prevent fetal haemoglobin depletion in preterm neonates. Results of the CB-TrIP study. British Journal of Haematology, n/a(n/a). https://doi.org/10.1111/bjh.16851 Cite
Abstract
Bookmark

No account yet? Register

0
Share
Share